Risk assessment in haemotopoietic stem cell transplantation: Disease and disease stage
- 30 June 2007
- journal article
- review article
- Published by Elsevier BV in Best Practice & Research Clinical Haematology
- Vol. 20 (2), 125-154
- https://doi.org/10.1016/j.beha.2006.10.003
Abstract
No abstract availableKeywords
This publication has 92 references indexed in Scilit:
- Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioningBlood, 2004
- Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myelomaBlood, 2003
- Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA groupBlood, 2003
- HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimenBlood, 2003
- Targeting the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaThe New England Journal of Medicine, 2001
- A Prognostic Score for Advanced Hodgkin's DiseaseThe New England Journal of Medicine, 1998
- Induction of graft-versus-leukemia effect in a patient with chronic lymphocytic leukemiaBone Marrow Transplantation, 1997
- Graft-versus-myeloma effectThe Lancet, 1996
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaThe New England Journal of Medicine, 1995
- Bone Marrow Transplantation for Patients with Chronic Myeloid LeukemiaThe New England Journal of Medicine, 1986